Trial Profile
Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel
- Indications Gastric cancer
- Focus Therapeutic Use
- 08 Jun 2021 Primary endpoint (progress free survival(PFS)) has not been met as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Status changed from recruiting to completed as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology